Cargando…
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While...
Autores principales: | Iwasaka, Sho, Shono, Yuji, Tokuda, Kentaro, Nakashima, Kosuke, Yamamoto, Yuzo, Maki, Jun, Nagasaki, Yoji, Shimono, Nobuyuki, Akahoshi, Tomohiko, Taguchi, Tomoaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409929/ https://www.ncbi.nlm.nih.gov/pubmed/32893123 http://dx.doi.org/10.1016/j.jiac.2020.08.001 |
Ejemplares similares
-
Efficacy of thromboelastography in the management of anticoagulation for veno-venous extracorporeal membrane oxygenation in a coronavirus disease 2019 patient: A case report
por: Nakashima, Ryosuke, et al.
Publicado: (2021) -
Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
por: Ghali, George Zaki, et al.
Publicado: (2020) -
Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021) -
Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
por: Shioya, Nobuki, et al.
Publicado: (2022) -
Retraction: Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
Publicado: (2021)